Clinical Trials Logo

Clinical Trial Summary

Barrett Esophagus is a common pathology, with an estimated prevalence of 1.6% at risk of progression to precancerous mucosa (low to high grade dysplasia). The incidence of adenocarcinoma on BE is 0.5% per year. In the event of dysplasia or cancer in situ, it is currently recommended at international and particularly European level to eradicate BE. The treatment techniques used to date carry out thermal destruction of the BE, in particular by radiofrequency. Eradication of dysplasia is achieved in 81% to 100% and disappearance of BE in 73% to 87% of cases. It requires an average of 3 destruction sessions. RF does not allow histological analysis after destruction of BE, but the risk of progression to neoplasia is estimated at 7.8/1000 persons per year. This risk could be due to the presence of glands buried in the esophageal mucosa. Indeed, these glands are not destroyed by thermal ablation methods, and remain invisible during endoscopic controls. A new treatment technique using the Endorotor® system allows mechanical resection of the entire mucosa in one session of treatment. In addition, the cost of these thermal destruction techniques currently limits their wider diffusion. It is therefore legitimate to propose a less expensive and probably more effective alternative technique.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04867590
Study type Interventional
Source University Hospital, Angers
Contact Elodie CESBRON-METIVIER, Ph.D.
Phone +33241353148
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date May 2021
Completion date July 2024

See also
  Status Clinical Trial Phase
Suspended NCT03554356 - Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE) N/A
Completed NCT03015389 - Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Tissue Analysis (WATS3D) For the Detection of High Grade Esophageal Dysplasia and Adenocarcinoma
Completed NCT03434834 - OCT Pilot in Esophagus N/A
Enrolling by invitation NCT04642690 - Nitrates and IL-8 in Barrett's Esophagus
Recruiting NCT02310230 - An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy N/A
Completed NCT00217087 - Endoscopic Therapy of Early Cancer in Barretts Esophagus Phase 2
Recruiting NCT02284802 - Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy N/A
Active, not recruiting NCT04151524 - Classification of Adenocarcinoma of the Esophagogastric Junction
Completed NCT00955019 - Novel Method of Surveillance in Barrett's Esophagus Phase 2
Terminated NCT00386594 - Pilot Study of Oral 852A for Elimination of High-Grade Dysplasia in Barrett's Esophagus N/A
Completed NCT00576498 - Novel Imaging Techniques in Barrett's Esophagus N/A
Not yet recruiting NCT04001478 - Non-invasive Testing for Early oEesophageal Cancer and Dysplasia
Completed NCT03859557 - The Evaluation of Patients With Esophageal and Foregut Disorders With WATS (Wide Area Transepithelial Sample With 3-Dimensional Computer-Assisted Analysis) vs. 4-Quadrant Forceps Biopsy
Completed NCT04587310 - Does Laparoscopic Sleeve Gastrectomy Lead to Barrett's Esophagus, 5-year Esophagogastroduodenoscopy Findings: A Retrospective Cohort Study
Enrolling by invitation NCT04392167 - a/LCI-OCT Pilot in Esophagus N/A
Recruiting NCT01618643 - Aceto-whitening in the Assessment of Gastrointestinal Neoplasia N/A
Terminated NCT01129778 - Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus N/A
Completed NCT00795184 - Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy N/A
Completed NCT00233935 - Defined Green Tea Catechin Extract in Preventing Esophageal Cancer in Patients With Barrett's Esophagus Phase 1
Completed NCT00489268 - Micro-Layer Ablation of Barrett's Metaplasia- A Two-Phase, Multi-Center Trial - Extension of Follow-up to 5 Years N/A